Skip to content 
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation. more
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 1.54M | 1.30M | 431.38K | - | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.05,"profit":true},{"date":"2023-12-31","value":27.98,"profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Cost of Revenue | 1.46M | 1.22M | 420.81K | 255.05K | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.29,"profit":true},{"date":"2023-12-31","value":28.82,"profit":true},{"date":"2024-12-31","value":17.47,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Gross Profit | 81.85K | 80.06K | 10.57K | (255.00K) | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.81,"profit":true},{"date":"2023-12-31","value":12.91,"profit":true},{"date":"2024-12-31","value":-311.53,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Gross Margin | 5.31% | 6.18% | 2.45% | - | - | [{"date":"2021-12-31","value":85.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":39.65,"profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Operating Expenses | 19.29M | 17.25M | 10.61M | 3.54M | 1.82M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":89.45,"profit":true},{"date":"2023-12-31","value":55.02,"profit":true},{"date":"2024-12-31","value":18.36,"profit":true},{"date":"2025-12-31","value":9.42,"profit":true}] |
| Operating Income | (19.21M) | (17.51M) | (10.60M) | (3.80M) | (1.82M) | [{"date":"2021-12-31","value":-1920700000,"profit":false},{"date":"2022-12-31","value":-1750911300,"profit":false},{"date":"2023-12-31","value":-1060100000,"profit":false},{"date":"2024-12-31","value":-379600000,"profit":false},{"date":"2025-12-31","value":-181752800,"profit":false}] |
| Total Non-Operating Income/Expense | - | 6.13M | 6.14M | (507.92K) | 345.38K | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":99.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-8.27,"profit":false},{"date":"2025-12-31","value":5.63,"profit":true}] |
| Pre-Tax Income | (27.11M) | (11.53M) | (4.34M) | (4.16M) | (1.38M) | [{"date":"2021-12-31","value":-2711400000,"profit":false},{"date":"2022-12-31","value":-1152500000,"profit":false},{"date":"2023-12-31","value":-434100000,"profit":false},{"date":"2024-12-31","value":-415800000,"profit":false},{"date":"2025-12-31","value":-137643000,"profit":false}] |
| Income Taxes | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income After Taxes | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | - | (11.53M) | (4.34M) | (4.16M) | (1.38M) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1152510200,"profit":false},{"date":"2023-12-31","value":-434097500,"profit":false},{"date":"2024-12-31","value":-415773700,"profit":false},{"date":"2025-12-31","value":-137643000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (25.05M) | (9.80M) | (2.83M) | (4.27M) | (1.36M) | [{"date":"2021-12-31","value":-2504800000,"profit":false},{"date":"2022-12-31","value":-980000000,"profit":false},{"date":"2023-12-31","value":-282500000,"profit":false},{"date":"2024-12-31","value":-426800000,"profit":false},{"date":"2025-12-31","value":-136327000,"profit":false}] |
| EPS (Diluted) | - | - | - | - | (1.24) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":-123.71,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| NIKI | |
|---|---|
| Cash Ratio | 0.75 |
| Current Ratio | 0.78 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| NIKI | |
|---|---|
| ROA (LTM) | -6.52% |
| ROE (LTM) | -10.79% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| NIKI | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.26 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 1.24 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| NIKI | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 23.35 |
| P/B | 0.32 |
| Price/FCF | NM |
| EV/R | 31.22 |
| EV/Ebitda | NM |
Niki BioSolutions, Inc. (NIKI) share price today is $8.98
Yes, Indians can buy shares of Niki BioSolutions, Inc. (NIKI) on Vested. To buy
Yes, you can purchase fractional shares of Niki BioSolutions, Inc. (NIKI) via the Vested app. You can start investing in Niki BioSolutions, Inc. (NIKI) with a minimum investment of $1.
You can invest in shares of Niki BioSolutions, Inc. (NIKI) via Vested in three simple steps:
The 52-week high price of Niki BioSolutions, Inc. (NIKI) is $44.7. The 52-week low price of Niki BioSolutions, Inc. (NIKI) is $6.
The price-to-earnings (P/E) ratio of Niki BioSolutions, Inc. (NIKI) is
The price-to-book (P/B) ratio of Niki BioSolutions, Inc. (NIKI) is 0.32
The dividend yield of Niki BioSolutions, Inc. (NIKI) is 0.00%
The market capitalization of Niki BioSolutions, Inc. (NIKI) is $7.02M
The stock symbol (or ticker) of Niki BioSolutions, Inc. is NIKI
Consider the share price of Niki BioSolutions, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Niki BioSolutions, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Niki BioSolutions, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Niki BioSolutions, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Niki BioSolutions, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Niki BioSolutions, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
